UPTRAVI Drug Patent Profile

Which patents cover Uptravi, and what generic alternatives are available?

Uptravi is a drug marketed by Actelion and is included in two NDAs. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and seventy-seven patent family members in forty-two countries.

The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the selexipag profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uptravi

A generic version of UPTRAVI was approved as selexipag by ALEMBIC on October 11^th, 2023.

Summary for UPTRAVI

International Patents:	177
US Patents:	6
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	5
Patent Applications:	510
Drug Prices:	Drug price information for UPTRAVI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for UPTRAVI
What excipients (inactive ingredients) are in UPTRAVI?	UPTRAVI excipients list
DailyMed Link:	UPTRAVI at DailyMed

See drug prices for UPTRAVI

Recent Clinical Trials for UPTRAVI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1
University of Newcastle Upon-Tyne	Phase 4
Sheffield Teaching Hospitals NHS Foundation Trust	Phase 4

See all UPTRAVI clinical trials

Pharmacology for UPTRAVI

Drug Class	Prostacyclin Receptor Agonist
Mechanism of Action	Prostacyclin Receptor Agonists

Paragraph IV (Patent) Challenges for UPTRAVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
UPTRAVI	For Injection	selexipag	1.8 mg/vial	214275	1	2022-07-29
UPTRAVI	Tablets	selexipag	0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg	207947	4	2019-12-23

US Patents and Regulatory Information for UPTRAVI

UPTRAVI is protected by six US patents and three FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-007	Dec 21, 2015	AB	RX	Yes	No	9,284,280*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-003	Dec 21, 2015	AB	RX	Yes	No	10,821,108*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes	9,284,280*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-004	Dec 21, 2015	AB	RX	Yes	No	10,828,298*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015	AB	RX	Yes	No
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-004	Dec 21, 2015	AB	RX	Yes	No	7,205,302*PED				Y

EU/EMA Drug Approvals for UPTRAVI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen Cilag International NV	Uptravi	selexipag	EMEA/H/C/003774Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,	Authorised	no	no	no	2016-05-12

International Patents for UPTRAVI

When does loss-of-exclusivity occur for UPTRAVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering UPTRAVI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016366073
Brazil	112018009534
Canada	3005169
Chile	2018001464
China	108289890
Colombia	2018006834

Supplementary Protection Certificates for UPTRAVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1400518	300836	Netherlands		PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
1400518	93266	Luxembourg		PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
1400518	CA 2016 00048	Denmark		PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
1400518	16C0042	France		PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519
1400518	122016000077	Germany		PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
1400518	1690044-1	Sweden		PRODUCT NAME: SELEXIPAG OR SALT THEROF; REG. NO/DATE: EU/1/15/1083 20160519

UPTRAVI market dynamics and financial trajectory: sales trends, pricing drivers, competition, and exclusivity risk

Last updated: July 2, 2026

UPTRAVI (selexipag; oral prostacyclin receptor agonist) has delivered consistent, category-relevant growth driven by uptake in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) populations. The next phase of financial trajectory is shaped by (1) patent/exclusivity cliffs for selexipag, (2) competitive pressure from PAH combination regimens, (3) payer and site-of-care tactics in high-cost specialty drugs, and (4) substitution risk if oral prostacyclin-class alternatives gain formulary position.

Market snapshot used for financial trajectory framing (what to watch in reporting)

• Primary revenue pool: PAH and CTEPH therapies in the US, EU, and select ex-US markets where oral prostacyclin pathway drugs maintain formulary penetration.
• Revenue quality: specialty pharmacy distribution, high persistence in long-duration PAH care, and pack-level pricing sensitivity to WAC-to-NADAC dynamics.
• Key performance levers: net price (rebates), channel mix, persistence, and conversion from monotherapy to combination regimens.

---

How has UPTRAVI performed financially since launch?

UPTRAVI’s financial trajectory is typically analyzed as a function of two overlapping demand curves:

1. Diagnosed prevalence and treatment initiation in PAH and CTEPH.
2. Dose titration and persistence once patients tolerate therapy, since prostacyclin-class drugs are used long term.

Because UPTRAVI is a specialty oral with chronic administration, the income statement pattern generally matches:

• upfront demand growth as prescribers adopt and patients start after diagnosis
• mid-cycle stability as the cohort matures on therapy
• incremental growth tied to combination uptake and guideline-driven intensification

Featured snippet answer: Financial trajectory for UPTRAVI has been driven less by one-off seasonality and more by durable persistence and incremental market share in oral prostacyclin pathway therapy for PAH and CTEPH.

What revenue drivers matter most for long-term specialty oral PAH products?

• Titration success rate: tolerability drives continuation; prostacyclin-class adverse effects create switching and discontinuation risk.
• Combination regimen movement: revenue accelerates when oral agents become add-ons to background endothelin receptor antagonists and PDE5 inhibitors.
• Payer behavior: preferred specialty tiers and prior authorization criteria determine net sales more than headline list pricing.

---

What UPTRAVI market dynamics are shaping sales growth and decline risk?

UPTRAVI’s market dynamics center on the PAH and CTEPH treatment algorithm and payer management of high-cost specialty products.

1) Treatment algorithm dynamics in PAH

• PAH is managed using background therapy combinations and prostacyclin pathway drugs as patients progress.
• Oral prostacyclin receptor agonists compete with:
  • oral PDE5 inhibitors
  • endothelin receptor antagonists
  • parenteral prostacyclin pathways (often used in higher-risk strata)

Oral agents tend to win early to mid-stage patients, while parenteral products remain anchored for severe disease. This mix can swing revenue growth depending on real-world progression profiles.

2) Payer and formulary dynamics

• Specialty drugs like UPTRAVI face rebate intensity and utilization management.
• Growth can slow if payers reclassify UPTRAVI on non-preferred tiers or tighten step edits.
• Net sales can diverge from prescription growth due to rebate and discount pressure.

3) Competitive substitution within prostacyclin pathway

UPTRAVI’s key competitive vector is not only direct “same mechanism” substitution but the broader “class-offense” strategy:

• competitors that offer simplified dosing or improved tolerability shift patient flows
• competitors that secure “preferred” formulary status can reduce UPTRAVI share gains

---

When does UPTRAVI lose exclusivity, and how does that timing affect financial trajectory?

A financial trajectory inflection for branded PAH specialty drugs typically aligns with:

• patent expiry
• regulatory exclusivity
• generic/authorized generic entry windows
• settlements that delay Paragraph IV outcomes

Critical business link: the closer UPTRAVI approaches patent or regulatory exclusivity end, the more management reporting shifts from growth narrative to “defend share” expense and access contracting.

What exclusivity cliffs typically change at entry readiness?

• ramp in defensive contracting with payers and PBMs
• increased price discounting to protect net price
• targeted patient support programs aligned to persistence
• potential shift in manufacturing allocations if competitor entry changes expected volume

---

What patents protect UPTRAVI, and what patent estate strengths drive leverage?

For a small-molecule branded oral like UPTRAVI, the patent estate typically clusters around:

• active ingredient composition and crystalline/polymorph aspects
• pharmaceutical compositions and formulation dosage forms
• method-of-use claims tied to PAH/CTEPH treatment protocols
• process/manufacturing claims

Featured snippet answer: UPTRAVI’s patent estate strength is a primary determinant of whether generics can launch quickly, and whether challengers can avoid design-around across dosage and method claims.

How formulation and method-of-use patents influence generic entry

• Formulation patents can delay “simple generic tablets” if specific excipients, dose-release characteristics, or stability requirements are claim-protected.
• Method-of-use patents can constrain “label carve-outs,” creating settlement pressure even when compound claims weaken.

---

How many competitors target the same patient segment as UPTRAVI?

UPTRAVI’s competitive set includes both:

1. Direct oral prostacyclin pathway agonists (competitive within mechanism and class)
2. Therapeutic-intent competitors in PAH/CTEPH such as endothelin receptor antagonists, PDE5 inhibitors, and parenteral prostacyclins depending on risk strata and guideline adoption.

Featured snippet answer: The practical competitive set is wider than “same mechanism.” UPTRAVI is most exposed where oral regimens replace parenteral prostacyclins and where oral combination strategies expand.

Competitive intensity drivers

• guideline revisions that favor earlier prostacyclin pathway use for certain risk profiles
• payer coverage policies that determine which combinations are feasible
• tolerability and adherence outcomes that shape switching behavior

---

What is the Orange Book status of UPTRAVI, and where are listing gaps?

UPTRAVI is expected to have an FDA Orange Book listing covering:

• drug substance and drug product patents
• method-of-use patents linked to approved indications

The Orange Book listing structure is a key map for:

• Paragraph IV challenge feasibility
• whether challengers can design around product and method claims
• settlement leverage for first-filing ANDA applicants

Featured snippet answer: Orange Book listings determine the legal “attack surface” for generics, shaping timing and likely litigation outcomes.

How Orange Book lists translate into launch risk

• More “in-force” patents tied to drug product and method-of-use reduce the chance of clean entry.
• Fewer active listings narrow the legal path and can accelerate generic incentives to file.

---

What Paragraph IV challenges affect UPTRAVI, and what settlement patterns are likely?

For branded small-molecules with durable chronic use, Paragraph IV challenges usually cluster around:

• earlier expiry of secondary patents (formulation or process)
• attempt to avoid method-of-use claim coverage by filing for label carve-outs

In PAH/CTEPH, settlements often follow a pattern:

• delay entry in exchange for a reverse payment or non-monetary consideration
• carve out specific strengths or labeling sections
• allow earlier launch of “at-risk” products in a narrow label scope

Featured snippet answer: The presence and timing of Paragraph IV cases are direct inputs to a sales volume decline profile once exclusivity erodes.

---

How do FDA regulatory pathways influence UPTRAVI’s commercial pressure?

UPTRAVI’s competitive pressure comes from the speed of generics and authorized generics that use Abbreviated New Drug Applications (ANDAs) for oral small molecules.

Key regulatory elements that influence market impact:

• whether challengers file for full-label or narrower indications
• whether reference product exclusivity delays approval even after patent barriers are resolved
• whether generic launch depends on bioequivalence completion and manufacturing readiness

---

What generic entry risks exist for UPTRAVI at different time horizons?

Risk is staged based on the legal sequence:

1. Near-term (before major patent expiry): primarily litigation-driven risk with limited volume impact unless there is an authorized or at-risk entry.
2. Mid-term (approaching composition/product expiry): higher likelihood of settlements that move entry earlier.
3. Post-expiry: broad generic availability tends to cause price compression and rapid share loss.

Featured snippet answer: The biggest financial step-down risk occurs when multiple in-force patents (product plus method) fall away or settle, enabling full-label generic approvals.

What a post-entry revenue curve typically looks like

• initial share erosion through substitution at pharmacy and prescriber levels
• net price pressure due to payer preference shifts
• rebound risk if brand leverages limited remaining patents (e.g., formulation tweaks) or access contracts

---

How does UPTRAVI compare with other PAH/CTEPH drugs on market dynamics?

UPTRAVI competes in a therapeutic area where revenue outcomes depend heavily on:

• dosing convenience and tolerability
• patient support and adherence
• payer coverage durability
• the extent of combination therapy adoption

Relative market dynamic comparison (directional)

• Oral agents (including UPTRAVI) tend to experience stronger penetration where outpatient oral intensification is favored.
• Parenteral prostacyclins may hold share in advanced-risk groups and hospital/center-based pathways.
• Category competition increases as payers negotiate across multiple specialty drugs within PAH.

---

What manufacturing and IP barriers could delay or enable UPTRAVI generics?

Even if patents fall, generic launch speed depends on:

• bioequivalence feasibility for each strength
• stability and formulation reproducibility
• scale-up and tablet manufacturing yields
• ability to match impurity profiles and dissolution characteristics

Featured snippet answer: Manufacturing readiness and formulation replicability can determine whether generic entry is “on time” or delayed, affecting the magnitude of the first post-launch year price shock.

---

Where are the highest revenue exposures for UPTRAVI geographically?

For specialty PAH drugs, geographic exposure usually concentrates in:

• US: highest price and rebate complexity, but major access channel scale
• EU5 and select markets: strong patient populations with payer systems that can tighten early
• Rest of world: growth can be steadier but often lower pricing per patient

Financial trajectory sensitivity is highest in markets with:

• earlier policy shifts to prefer competing oral therapies
• faster uptake of generics after patent expiry

---

Key takeaways: what to monitor in UPTRAVI’s next financial cycle

• UPTRAVI’s sales trajectory is driven by persistence and combination uptake in PAH/CTEPH, not short-cycle demand.
• Market dynamics favor whichever prostacyclin-pathway strategy payers and providers treat as “preferred.” Net price and access contracts can change faster than prescription volume.
• The largest financial risk window is the period leading into and immediately following exclusivity and patent cliffs, especially if Orange Book listings allow Paragraph IV pathways.
• Generic entry outcomes depend on the strength and breadth of formulation and method-of-use protection, plus manufacturing and bioequivalence readiness.
• Expect revenue step-down patterns where full-label generic approvals become feasible across major strengths, followed by rapid net price compression.

---

FAQs

1) What factors determine UPTRAVI net sales more than prescription growth?
Net price, rebate intensity, and payer utilization management tied to specialty tiering and prior authorization.

2) How does UPTRAVI dosing titration affect long-term revenue persistence?
Tolerance and dose escalation success affect continuation, which drives revenue cohort stability over time.

3) What is the main litigation driver for UPTRAVI around generic entry?
Whether method-of-use and drug product/formulation patents block full-label ANDA approval or induce label carve-outs and settlement delays.

4) Does UPTRAVI face higher risk from “same mechanism” competitors or broader PAH combination strategies?
Broader combination strategies are often the bigger practical threat because payer coverage and clinical intensification choices determine patient movement.

5) What market indicators signal that UPTRAVI is nearing a profitability inflection?
Escalating discounting, shifts in formulary status, increased defensive contracting spend, and disclosed timing in exclusivity/patent events.

---

References

No sources were provided in the prompt, and no external documents were cited.

DrugChatter Q&A for UPTRAVI

Drug patent length uptravi?
Uptravi loss of patent uk?
Uptravi generic competition?
Pharmaceutical v2 company uptravi?
Uptravi selexipag patent expiration date?